Market Cap : 8.28 B | Enterprise Value : 6.99 B | P/E (TTM) : 123.31 | P/B : 5.99 |
---|
NAS:IONS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:IONS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2021-01-27), Ionis Pharmaceuticals's Intrinsic Value: Projected FCF is $23.64. The stock price of Ionis Pharmaceuticals is $59.190000. Therefore, Ionis Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 2.5.
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Ionis Pharmaceuticals was 564.67. The lowest was 1.95. And the median was 11.95.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Ionis Pharmaceuticals's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Ionis Pharmaceuticals's Free Cash Flow(6 year avg) = $147.74.
Ionis Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Sep20) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (14.862653310476 | * | 147.7405 | + | 1383.149 | * | 0.8) | / | 139.708 | |
= | 23.64 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Ionis Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 59.190000 | / | 23.637408247318 | |
= | 2.50 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline